Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Results

Save Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial	Phase	Eligible Participant	Official Title	Drugs in Trial	Location
NCT02855944	III	Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)	ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	Colorado, Georgia
Drug(s) in Trial Other Drug Names Main Known Action Rucaparib AG-014699, PF 01367338, CO-338, Rubraca PARP inhibitor
NCT03398655	III	Platinum resistant ovarian cancer	A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer	View Drugs	Arizona, California, Connecticut, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Montana, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Ofranergene Obadenovec VB-111 Endothelin promoter-apoptotic receptor gene therapy Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02584478	IIa	Recurrent ovarian cancer	A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)	View Drugs	California, Florida, Louisiana, Texas
Drug(s) in Trial Other Drug Names Main Known Action Anlotinib AL3818 VEGFR2/3 kinase inhibitor Carboplatin Paraplatin, Novoplatinum DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02419417	IIa	Platinum resistant or refractory ovarian cancer with BRCA1/2 mutations	A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies	View Drugs	California, Colorado, Massachusetts, Oregon, Pennsylvania, South Carolina
Drug(s) in Trial Other Drug Names Main Known Action BMS-986158 BET inhibitor BMS-986158 BET inhibitor Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02091141	IIa	Advanced solid tumors with ALK mutations or high TMB	My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents	View Drugs	Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, Missouri, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Dakota, Tennessee, Texas, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Alectinib ALK inhibitor CH5424802, Alecensa, anaplastic lymphoma kinase inhibitor CH5424802, AF802 ALK kinase inhibitor Atezolizumab Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 Blocks PD-L1 inhibition of T cells
NCT02502266	II/III	Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	View Drugs	Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Cediranib Recentin, Cediranib maleate, AZD2171 VEGFR1-3 kinase inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT01037790	II	Advanced solid tumors with CCND1/2 AMP, CDK4/6 MUT, or other G1/S alterations	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Palbociclib Ibrance, PD0332991, PD-0332991 CDK4/6 inhibitor
NCT01953926	II	Advanced solid tumors with activating HER2 mutations	An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.	View Drugs	Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri, New York, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Neratinib HKI-272, PD272 EGFR, HER2, HER4 kinase inhibitor
NCT02203513	II	Recurrent high grade serous or endometrioid or germline BRCA1/2-mutated ovarian cancer	A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT02312245	II	Platinum resistant or refractory ovarian cancer	Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers	View Drugs	Arizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Gemcitabine Gemzar Ribonucleotide reductase and DNA synthesis inhibitor Liposomal doxorubicin Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride Topoisomerase II inhibitor Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Topotecan Hycamptamine, Hycamtin, TOPO Topoisomerase I inhibitor
NCT02272998	II	Advanced solid tumors with FGFR1-4, PDGFRa, Kit, RET, FLT3, or Abl1 alterations	Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)	View Drugs	Ohio
Drug(s) in Trial Other Drug Names Main Known Action Ponatinib multitargeted tyrosine kinase inhibitor AP24534, Iclusig, AP24534 Multi-targeted kinase inhibitor
NCT02079740	II	Advanced solid tumors with KRAS or NRAS mutations (in expansion)	An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Navitoclax Bcl-2 Family Protein Inhibitor ABT-263, A-855071.0, ABT-263 Bcl-2, Bcl-XL, and Bcl-w inhibitor Trametinib TMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist MEK1/2 inhibitor
NCT02485990	II	Platinum resistant, refractory, partially sensitive or persistent ovarian cancer (1 prior platinum-taxane)	An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT02571725	II	Recurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb)	A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer	View Drugs	Florida, New Mexico, Ohio, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT02568267	II	Advanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangements	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	View Drugs	Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action Entrectinib RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101 ALK, TRK, ROS1 kinase inhibitor
NCT02693535	II	Ovarian Expansion for BRCA MUT1/2 or CDKN2A loss or mutation or Advanced solid tumors with molecular alterations in ALK, ROS1, MET, CDK4, CDK6, CSF1R, PDGFR, VEGFR, mTOR, TSC, ERBB2, BRAFV600E/D/K/R, Bcr-abl, SRC, KIT, PDGFRB, RAF-1,BRAF, EPHA2, FYN, LCK, YES1, RET, ATM, POLD, POLE, high TMB, MSI high)	Targeted Agent and Profiling Utilization Registry (TAPUR) Study	View Drugs	Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana, Massachusetts, Michigan, Nebraska, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Washington
Drug(s) in Trial Other Drug Names Main Known Action Cetuximab Erbitux, Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225 EGFR antagonist Cobimetinib Cotellic, GDC-0973, XL518 MEK1 inhibitor Crizotinib c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori c-Met and ALK kinase inhibitor Dasatinib BMS-354825, Sprycel SRC and bcr-abl kinase inhibitor Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells Olaparib AZD2281, Lynparza PARP inhibitor Palbociclib Ibrance, PD0332991, PD-0332991 CDK4/6 inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells Pertuzumab Perjeta, monoclonal antibody 2C4, rhuMAb2C4 HER2 dimerization inhibitor Regorafanib BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga Multi-targeted RTK inhibitor Sunitinib Sutent, Sunitinib malate VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit Temsirolimus CCI-779, Torisel mTOR inhibitor Trastuzumab HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin HER2 antagonist Vemurafenib RO5185426, PLX4032, Zelboraf BRAF kinase inhibitor
NCT02465060	II	Advanced solid tumors with alterations in AKT, BRAF, cKIT, CDK4 AMP, CDK6 AMP, EGFR, ERBB2 AMP, FGFR1-4, FGFR1-4 AMP, MET, MET AMP, mTOR, NTRK1-3, PIK3CA, PTCH1, PTEN, SMO, TSC1/2	Molecular Analysis for Therapy Choice (MATCH)	View Drugs	Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Afatinib BIBW 2992 MA2, Gilotrif, Afatinib dimaleate EGFR, HER2, HER4 kinase inhibitor Copanlisib BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 pan-PI3K inhibitor Crizotinib c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori c-Met and ALK kinase inhibitor Erdafitinib pan-FGFR tyrosine kinase inhibitor JNJ-42756493 pan-FGFR kinase inhibitor Ipatasertib GDC-0068, Akt Inhibitor GDC-0068, RG7440 pan-AKT inhibitor Larotrectinib Trk inhibitor LOXO-101 Pan-Trk kinase inhibitor Osimertinib Tagrisso, AZD9291, EGFR inhibitor AZD9291, Mereletinib EGFR kinase inhibitor Palbociclib Ibrance, PD0332991, PD-0332991 CDK4/6 inhibitor Pertuzumab Perjeta, monoclonal antibody 2C4, rhuMAb2C4 HER2 dimerization inhibitor Sapanisertib TAK-228, MLN0128, TORC1/2 Inhibitor MLN0128, TORC1/2 Inhibitor INK128, INK128 TORC1/2 kinase inhibitor Sunitinib Sutent, Sunitinib malate VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit Trastuzumab HER2 Monoclonal Antibody, Anti-erbB2 Monoclonal Antibody, Herceptin HER2 antagonist Trastuzumab emtansine ado trastuzumab emtansine, Kadcyla, T-DM1, trastuzumab-DM1, trastuzumab-MCC-DM1, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1 immunoconjugate ADC: anti-HER2 + microtubule destabilizer (DM1) Ulixertinib BVD-523, ERK inhibitor BVD-523 ERK inhibitor Vismodegib Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 Smoothened antagonist
NCT02628067	II	Advanced solid tumors with high MSI	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	View Drugs	California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New Mexico, Texas
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02576444	II	Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations	A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors	View Drugs	Connecticut, Massachusetts, Ohio, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor Capivasertib Akt inhibitor AZD5363 pan-AKT inhibitor Ceralasertib AZD6738 ATR kinase inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT02554812	II	Advanced solid tumors (in ovarian expansion)	A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies	View Drugs	California, District of Columbia, Florida, Iowa, Michigan, New York, North Carolina, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells PD-0360324 anti–M-CSF mAb PD-0360324, anti-CSF1 monoclonal antibody PD-0360324 CSF1R antagonist and tumor-associated macrophage inhibitor PF-04518600 anti-OX40 antibody PF-04518600 Stimulates OX40 to increase T cell activation and immune response
NCT02832167	II	Advanced solid tumors	An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies	View Drugs	Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia
Drug(s) in Trial Other Drug Names Main Known Action Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT01827384	II	Advanced solid tumors with mutations in BRAF, KRAS, NRAS, NF1, PIK3CA, AKT1, MTOR, FBXW7, PTEN, ATM, ATR, ERCC1, MLH1, MSH2, NBN, RAD51, PARP1/2,TP53	Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors	View Drugs	Colorado, Kentucky, Maryland, Missouri, New Jersey, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor Carboplatin Paraplatin, Novoplatinum DNA damaging agent Everolimus Zortress, RAD001, Certican, Afinitor mTOR inhibitor Temozolomide Temodal, Temodar, Methazolastone DNA damaging agent Trametinib TMT212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist MEK1/2 inhibitor Veliparib ABT-888 PARP inhibitor
NCT02873962	II	Platinum resistant or partially sensitive ovarian cancer	A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells Rucaparib AG-014699, PF 01367338, CO-338, Rubraca PARP inhibitor
NCT02873975	II	Advanced solid tumors with MYC or CCNE1 amplification, Rb loss, or FBXW7, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHEK2, Fanconi anemia pathway mutations	A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Prexasertib checkpoint kinase 1 inhibitor LY2606368, LY2606368 Chk1/2 inhibitor
NCT01851369	II	Advanced solid tumors and granulosa cell ovarian cancer (in expansion)	A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action methoxyamine TRC102 Base excision repair inhibitor Temozolomide Temodal, Temodar, Methazolastone DNA damaging agent
NCT02901899	II	Platinum resistant ovarian cancer	An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer	View Drugs	Illinois
Drug(s) in Trial Other Drug Names Main Known Action Guadecitabine DNA methyltransferase inhibitor SGI-110, SGI-110 DNA methylation inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02364713	II	Platinum resistant, refractory or persistent ovarian cancer (disease outside the peritoneal cavity)	A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	View Drugs	Arizona, Florida, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action MV-NIS oncolytic measles virus encoding thyroidal sodium iodide symporter Induces immune response and tumor cell lysis
NCT02834013	II	Advanced ovarian germ cell, mucinous, squamous cell, or adenocarcinoma	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	View Drugs	Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT02900560	II	Platinum resistant or refractory ovarian cancer (< 3 prior therapies for platinum resistant disease)	Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	View Drugs	California, Maryland, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Oral Azacitidine CC-486 DNA methylation inhibitor Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT02843165	II	Advanced solid tumors with lesion treatable with radiation therapy	Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 Blocks PD-L1 inhibition of T cells Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells Radiation Therapy Radiotherapy, Irradiation
NCT03026062	II	Platinum resistant or refractory ovarian cancer	Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Durvalumab Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Tremelimumab anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab Blocks CTLA-4 inhibition of T cells
NCT03093155	II	Platinum resistant, refractory or persistent ovarian cancer	A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers	View Drugs	Connecticut, Maryland
Drug(s) in Trial Other Drug Names Main Known Action Bevacizumab immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin VEGF antagonist Ixabepilone Ixempra, Epothilone-B, epothilone B lactam, BMS-247550, Azaepothilone B Microtubule stabilizer/mitotic inhibitor
NCT02920996	II	Advanced solid tumors with NTRK1-3 rearrangements	A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Merestinib c-Met inhibitor LY2801653, LY2801653 Multi-targeted RTK inhibitor
NCT02587598	II	Advanced solid tumors (in expansion)	A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies	View Drugs	Arizona, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan, Nebraska, Ohio, Oklahoma, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Azacytidine azacitidine, Vidaza, Mylosar, 5-AZC DNA methylation inhibitor INCB053914 pan-PIM inhibitor INCB053914 PIM1, 2, 3 inhibitor
NCT03113487	II	Platinum resistant ovarian cancer	P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action p53MVA Modified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53 Immune response against p53 tumor antigen Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03212274	II	Advanced solid tumors with IDH1 or IDH2 mutations	A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors	View Drugs	California, Connecticut, District of Columbia, Kentucky, Maryland, Massachusetts, New Jersey, North Carolina, Ohio, Pennsylvania, Tennessee, Texas, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Olaparib AZD2281, Lynparza PARP inhibitor
NCT03253679	II	Advanced solid tumors with CCNE1 AMP	A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification	View Drugs	California, Colorado, District of Columbia, Florida, Kentucky, New York, North Carolina, Pennsylvania, Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor
NCT03274661	II	Advanced solid tumors	Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency	View Drugs	Florida
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03146663	II	Platinum resistant high grade serous or endometrioid ovarian cancer (at least 3 prior therapies)	A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer	View Drugs	Arizona, California, Colorado, Florida, Illinois, Minnesota, Missouri, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action NUC-1031 gemcitabine ProTide, Acelarin, gemcitabine-phosphoramidate NUC-1031 Ribonucleotide reductase and DNA synthesis inhibitor
NCT03284385	II	Advanced solid tumors with SETD2 deficiency	A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies	View Drugs	California, District of Columbia, Illinois, Maryland, Massachusetts, Missouri, Pennsylvania, Tennessee
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor
NCT03310879	II	Advanced solid tumors with CCND1, CCND2, or CCND3 alterations or CDK4/6 amplifications	A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6	View Drugs	Massachusetts
Drug(s) in Trial Other Drug Names Main Known Action Abemaciclib Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio CDK4/6 inhibitor
NCT03355976	II	Recurrent clear cell ovarian cancer	BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas	View Drugs	Rhode Island
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03147976	II	Advanced solid tumors with MET over-expression or mutation	A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) Mutations	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action AMG 337 c-Met kinase inhibitor
NCT03395080	II	Platinum resistant or refractory ovarian cancer, or carcinosarcoma at first recurrence	A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma	View Drugs	Alabama, Arizona, Florida, Illinois, Massachusetts, Missouri, Ohio, Oklahoma, Tennessee, Texas, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action DKN-01 DKK1-neutralizing monoclonal antibody DKN-01 Dickkopf-1 (DKK1) antagonist Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03412877	II	Advanced solid tumors	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer	View Drugs	Maryland
Drug(s) in Trial Other Drug Names Main Known Action TCR-transduced PBL Anti-tumor immune response
NCT03428802	II	Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations	A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability	View Drugs	New Jersey
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03462342	II	Recurrent ovarian cancer	Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer	View Drugs	Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Ceralasertib AZD6738 ATR kinase inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT01876511	II	Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB	Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors	View Drugs	California, Maryland, New York, Ohio, Oregon, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action Pembrolizumab MK3475, SCH 900475, Lambrolizumab, Keytruda Blocks PD-L1/2 inhibition of T cells
NCT03570619	II	Advanced solid tumors with CDK12 alterations	IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations	View Drugs	Florida, Michigan, New York
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03565991	II	Advanced solid tumors with BRCA1/2 or ATM mutations	A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors	View Drugs	California, Georgia, Louisiana, Massachusetts, Missouri, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Avelumab Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio Blocks PD-L1 inhibition of T cells Talazoparib Talazoparib Tosylate, BMN-673, MDV3800 PARP inhibitor
NCT03579316	II	Recurrent ovarian cancer (PD on or after prior PARP inhibitor)	A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition	View Drugs	Massachusetts, Texas
Drug(s) in Trial Other Drug Names Main Known Action Adavosertib WEE1 inhibitor AZD1775, MK1775, AZD1775 WEE1 inhibitor Olaparib AZD2281, Lynparza PARP inhibitor
NCT03610490	II	Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma	Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action MDA-TIL autologous tumor-infiltrating lymphocytes MDA-TIL Anti-tumor immune response
NCT03651271	II	Recurrent ovarian cancer with high MSI	An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer	View Drugs	California, Massachusetts, New York, Texas
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03668119	II	Advanced solid tumors with high TMB	A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	View Drugs	California, Colorado, Illinois, Minnesota, New York, North Carolina, Oregon, Tennessee, Texas
Drug(s) in Trial Other Drug Names Main Known Action Ipilimumab Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy Blocks CTLA-4 inhibition of T cells Nivolumab BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo Blocks PD-L1/2 inhibition of T cells
NCT03587311	II	Platinum resistant or refractory mesothelin+ high grade serous or endometroid ovarian cancer	A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer